Ensol Biosciences Inc. Logo

Ensol Biosciences Inc.

Develops AI-discovered peptide drugs for cancer, osteoarthritis, and Alzheimer's disease.

140610 | KO

Overview

Corporate Details

ISIN(s):
KR7140610007
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노10로 51(탑립동), 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Ensol Biosciences Inc. is a clinical-stage biopharmaceutical company developing innovative drugs for diseases with high unmet medical needs. The company specializes in creating PPI (Protein-Protein Interaction)-regulating short peptide drugs, utilizing a proprietary bio big data and AI platform for discovery and development. Its therapeutic approach focuses on local, non-blood injections to maximize efficacy, ensure high target specificity, and minimize systemic side effects due to a short half-life in the bloodstream. Ensol's clinical pipeline targets conditions such as osteoarthritis, degenerative disc disease, cancer, and Alzheimer's disease. Key candidates include E1K for osteoarthritis (preparing for Phase 3) and C1K, a combination cancer therapy (Phase 1).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.6 KB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-06 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 67.6 KB
2025-08-06 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB
2025-07-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB
2025-07-22 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 38.5 KB
2025-07-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.3 KB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-18 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB
2025-07-10 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 31.0 KB
2025-06-12 00:00
Major Shareholding Notification
최대주주변경
Korean 22.0 KB
2025-06-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 84.8 KB
2025-06-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 67.9 KB
2025-06-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-11 00:00
Major Shareholding Notification
최대주주변경을수반하는주식양수도계약체결
Korean 9.3 KB

Automate Your Workflow. Get a real-time feed of all Ensol Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ensol Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ensol Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ziccum AB Logo
Licenses ambient drying tech for pharma to create stable, cold-chain-free biologics.
Sweden
ZICC
グロービング株式会社 Logo
Accelerates business growth via strategic consulting, AI implementation, and proprietary SaaS.
Japan
277A
株式会社D&Mカンパニー Logo
Optimizing healthcare & welfare businesses via finance, consulting, and HR solutions.
Japan
189A
株式会社Veritas In Silico Logo
An in silico drug discovery platform creating mRNA-targeting medicines with pharma partners.
Japan
130A
株式会社タイミー Logo
On-demand staffing platform connecting businesses and workers for flexible spot work.
Japan
215A
株式会社ユカリア Logo
Management, DX, and data solutions for healthcare and long-term care providers.
Japan
286A
株式会社レント Logo
Rents industrial & construction machinery and provides inspection services for various industries.
Japan
372A

Talk to a Data Expert

Have a question? We'll get back to you promptly.